TECHNOLOGY
These standardised indicators will help businesses navigate evolving regulatory requirements while providing transparency to stakeholders.
“ Nature loss and climate change present big challenges for the pharmaceutical sector,” says Will Evison, Director of Climate, Environment & Nature Strategy at PwC.
“ Addressing these twin crises proactively can improve health outcomes and drive value creation.”
Pharmaceutical packaging, expired medications and production waste contribute to significant environmental harm.
Companies are encouraged to invest in circular economy initiatives, such as biodegradable packaging and take-back programmes for unused medicines.
What are the industry’ s next steps? One of the roadmap’ s next steps is to establish clear nature-related metrics for tracking and reporting progress.
A pivotal moment for the pharmaceutical sector While the roadmap does not mandate specific targets, it provides a flexible framework for pharmaceutical companies to align their sustainability efforts with global environmental objectives.
As regulatory pressure and investor expectations continue to grow, the industry faces a pivotal moment in its sustainability journey.
The success of these initiatives will depend on corporate commitment, cross-sector collaboration and the ability to translate strategy into tangible action.
“ Collaboration is key to making progress,” says Claire.
“ We now have an even clearer understanding of how to accelerate the priority actions that we can take together for nature, people and business resilience.”
healthcare-digital. com 93